Sermorelin

Background

Sermorelin (also called growth hormone–releasing factor 1‑29, GRF 1‑29 or sermorelin acetate) is a synthetic peptide corresponding to the N‑terminal 29 amino acids of endogenous human growth hormone–releasing hormone (GHRH, also termed GRF).[5][10] This 29‑residue fragment contains the full biological activity of native 44‑amino‑acid GHRH at the pituitary receptor.[5] Sermorelin was developed in the context of intensive work on GHRH structure–activity relationships in the 1980s, which showed that N‑terminally truncated or C‑terminally extended analogues could modulate potency and stability.[5]

Therapeutically, sermorelin was introduced as a GHRH analogue for the diagnostic evaluation and treatment of growth hormone (GH) deficiency, particularly in pediatrics.[10] An injectable formulation (Geref, sermorelin acetate) was approved in the United States in the 1990s for diagnostic use in children with suspected GH deficiency, but the product was subsequently discontinued for commercial reasons, not for specific safety concerns.[11][10]

Mechanism of action

Sermorelin is a selective agonist at the GHRH receptor (GHRHR) on anterior pituitary somatotrophs.[5][12] Binding of sermorelin to GHRHR activates a Gs protein–coupled signaling cascade, increasing intracellular cyclic AMP (cAMP), activating protein kinase A, and stimulating GH gene transcription and exocytosis.[12] In cultured somatotrophs, native GRF (and by inference GRF 1‑29 analogues) increases thymidine incorporation and cell proliferation, indicating a mitogenic effect on GH‑producing cells mediated by cAMP.[12]

Physiologically, sermorelin mimics hypothalamic GHRH to stimulate pulsatile GH secretion from the pituitary, which in turn induces hepatic and peripheral production of insulin‑like growth factor‑1 (IGF‑1).[4] Unlike exogenous recombinant human GH (rhGH), sermorelin leaves hypothalamic–pituitary feedback mechanisms intact, so that elevated IGF‑1 and GH exert negative feedback on GHRH and GH release via somatostatin and other regulators.[4] This results in a ceiling effect and more physiologic GH and IGF‑1 profiles compared with direct GH administration.[4]

Sermorelin has a relatively short plasma half‑life (on the order of minutes), similar to native GHRH, and is subject to rapid enzymatic degradation and renal clearance.[11] Medicinal chemistry efforts have produced longer‑acting, more potent GHRH analogues (e.g., CJC‑1293, CJC‑1295, tesamorelin) with substitutions at key residues to enhance stability.[5][10]

Evidence summary

Preclinical data

Early structure–activity studies examined multiple analogues of hGHRH(1‑29)-NH₂, including sermorelin, in superfused rat pituitary cell systems.[5] In one series, numerous modified 1‑29 analogues incorporating amino acid substitutions at positions 1, 15, 27, 28, and 29 were synthesized and shown to be more potent than native hGHRH(1‑29)-NH₂ in stimulating GH release in vitro and in vivo in rats.[5] These experiments established that the 1‑29 fragment contained the receptor‑binding and activation determinants necessary for full GH‑releasing activity.

Additional work demonstrated that GHRH/GRF exerts a mitogenic effect on cultured somatotrophs.[12] In an in vitro study of cultured rat GH‑producing cells, GRF increased [³H]thymidine uptake and cell proliferation compared with controls and somatostatin‑treated cultures, with corresponding maintenance of GH content and secretion over time.[12] These data support the concept that chronic GHRH analogue exposure can influence somatotroph number and function.

Clinical data in GH deficiency

Published, controlled trials of sermorelin in humans are limited and predominantly involve children with suspected or confirmed GH deficiency or short stature; many predate current trial‑registration practices, so details on exact sample sizes and protocol names are incompletely indexed. Reviews of GHRH analogues and secretagogues describe sermorelin as effective in acutely stimulating GH and raising IGF‑1 in GH‑deficient pediatric populations when administered intravenously or subcutaneously for diagnostic testing and, in some studies, for therapeutic use over months.[4][6][10]

A narrative review comparing rhGH replacement with GHRH analogue therapy in adults with GH insufficiency references sermorelin as a prototype GHRH 1‑29 analogue that produces dose‑dependent increases in GH and IGF‑1, with a lower risk of supraphysiologic IGF‑1 exposure due to preserved feedback inhibition.[4] However, this review also notes the scarcity of large, long‑term randomized controlled trials of sermorelin for adult‑onset GH deficiency, especially compared with the extensive rhGH literature.[4]

Analytical and anti‑doping context

Because sermorelin and related GHRH analogues have potential for performance enhancement, methods for LC‑HRMS/MS detection in human plasma have been developed. One study used immunoaffinity purification followed by high‑resolution tandem mass spectrometry to qualitatively identify four GHRHs—Geref (sermorelin), CJC‑1293, CJC‑1295, and tesamorelin—and two metabolites in plasma.[11] This work demonstrated the feasibility of distinguishing intact peptides and degradation products, supporting anti‑doping and pharmacokinetic investigations.[11]

Overall, the human evidence base for sermorelin is modest, focused on acute GH stimulation, diagnostic testing, and small therapeutic series, with limited modern, large‑scale randomized trials.

Clinical and research uses

Approved and historical uses

Sermorelin (Geref) was FDA‑approved in the United States for the diagnostic evaluation of pituitary GH secretory capacity in pediatric patients with suspected GH deficiency.[10][11] The drug was administered as an intravenous or subcutaneous bolus, and serial GH measurements were obtained to distinguish hypothalamic from pituitary causes of GH deficiency. The product was subsequently withdrawn from the US market for commercial reasons.[10][11] There is no current evidence of active EMA centralized approval; sermorelin has not been a widely marketed product in the EU, where diagnostic and therapeutic management of GH deficiency has primarily used GH stimulation tests and rhGH therapy.

Off‑label and investigational contexts

Reviews of GH modulation describe GHRH analogues, including sermorelin, as investigational or off‑label tools for managing GH insufficiency in adults, particularly in the context of so‑called “age‑related” GH decline.[4] The rationale is that stimulating endogenous GH with preserved feedback may provide a more physiological profile and potentially fewer adverse effects than chronic rhGH replacement.[4] However, robust outcome data for sermorelin in this setting are lacking, and use for “anti‑aging” or performance enhancement remains off‑label and unsupported by high‑quality evidence.

In research, sermorelin serves as a pharmacological probe to study somatotroph responsiveness, GH pulsatility, and pituitary reserve, and as a comparator or scaffold for designing longer‑acting GHRH analogues.[5][10][11]

Dosing context

The following dosing information is derived from published literature and historical labeling and is provided only as contextual information, not as prescribing guidance.

• Diagnostic use (pediatrics): Historical protocols for Geref employed intravenous or subcutaneous bolus doses (e.g., in the range of micrograms per kilogram) to elicit GH peaks for stimulation testing.[4][10][11] Exact labeled doses vary by source and are not fully detailed in current open‑access documents.
• Therapeutic studies: In small clinical series, subcutaneous daily or intermittent sermorelin injections were used to raise IGF‑1 toward age‑adjusted norms in GH‑deficient subjects, with doses titrated to GH/IGF‑1 responses rather than fixed body‑weight criteria.[4] Published descriptions emphasize dose‑dependent GH responses and the use of feedback‑guided titration.[4]

No standardized, evidence‑based dosing regimens for chronic sermorelin therapy have been established in large randomized trials.

Safety profile

Adverse effects

Based on experience with GHRH analogues and limited clinical use, reported adverse effects of sermorelin are generally mild and transient, and largely similar to those of other peptide injectables:[4][10]

• Injection‑site reactions (pain, erythema, swelling)
• Flu‑like symptoms (transient headache, malaise)
• Transient flushing or warm sensation
• Nausea or mild gastrointestinal discomfort

Because sermorelin stimulates endogenous GH, its longer‑term safety profile is expected to resemble that of moderate elevations in GH and IGF‑1, rather than continuous supraphysiologic exposure as may occur with inappropriate rhGH dosing.[4] Theoretical risks, extrapolated from GH biology and rhGH experience, include:[4][10]

• Exacerbation of pre‑existing malignancies or promotion of occult tumor growth due to IGF‑1–mediated mitogenic and anti‑apoptotic effects
• Worsening of diabetes mellitus or impaired glucose tolerance
• Fluid retention–related effects (edema, arthralgia) at higher or sustained GH levels

However, specific, long‑term, sermorelin‑attributable toxicities have not been well characterized, given limited chronic use data.

Contraindications and cautions (conceptual)

Formal, up‑to‑date contraindication lists for sermorelin are not available in current regulatory labeling because the product is discontinued. Conceptually, based on mechanism and GH physiology, sermorelin would be contraindicated or used with great caution in:[4][10]

• Patients with active malignancy, especially GH‑ or IGF‑1–responsive tumors
• Individuals with proliferative or pre‑proliferative diabetic retinopathy
• Patients with uncontrolled diabetes mellitus or significant intracranial hypertension
• Situations where GH stimulation tests are unnecessary or potentially harmful (e.g., decompensated critical illness)

Use in pregnancy, lactation, or in young children outside validated diagnostic protocols lacks robust safety data.

Regulatory status

United States

Sermorelin acetate (Geref) previously held FDA approval as a diagnostic agent to evaluate pituitary GH secretory function in children with suspected GH deficiency.[10][11] The product has been discontinued from the US market, and no current FDA‑listed sermorelin product is commercially available as an approved drug.[10] Compounded formulations may be produced in some settings, but these are not FDA‑approved products, and their quality and regulatory status differ from that of previously approved Geref.

Sermorelin is included in anti‑doping analytical panels as a prohibited peptide hormone in sport, and detection methodologies in human plasma have been described.[11]

European Union and other regions

There is no evidence of an active EMA centralized marketing authorization for sermorelin as of recent reviews of approved peptide therapeutics.[10] Management of GH deficiency in the EU primarily relies on GH stimulation tests with other agents and treatment with rhGH rather than GHRH analogues.

Globally, GHRH analogues such as tesamorelin have obtained approval for specific indications (e.g., HIV‑associated lipodystrophy), but sermorelin itself is not currently marketed as an approved therapeutic in major jurisdictions.[10]